Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial .

NCT00344526 is registered in ClinicalTrials.gov with University Hospital, Limoges as lead sponsor.

NCT NCT00344526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00344526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial .
Lead sponsor
University Hospital, Limoges
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2000
Completion date
June 30, 2006
Enrollment
100
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

primary systemic amyloidosis (al)